Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer (Q35032865)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

pancreatic cancer

1 reference

based on heuristic

inferred from title

author name string

Colin D Weekes

1

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Sujatha Nallapareddy

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Michelle A Rudek

3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Alexis Norris-Kirby

4

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Daniel Laheru

5

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Antonio Jimeno

6

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Ross C Donehower

7

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Kathleen M Murphy

8

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Manuel Hidalgo

9

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Sharyn D Baker

10

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Wells A Messersmith

11

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

publication date

23 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1057-1065

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

Cellular pharmacology of gemcitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

RecQ helicases: multiple roles in genome maintenance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

RecQ helicases: caretakers of the genome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

ATM and related protein kinases: safeguarding genome integrity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

Defending genome integrity during DNA replication: a proposed role for RecQ family helicases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

8 July 2018

Pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9413-7

21 January 2018

Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9413-7

21 January 2018

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9413-7

21 January 2018

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9413-7

21 January 2018

Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9413-7

21 January 2018

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9413-7

21 January 2018

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9413-7

21 January 2018

Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9413-7

21 January 2018

Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9413-7

21 January 2018

Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9413-7

21 January 2018

Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9413-7

21 January 2018

Thymidylate synthase 5'- and 3'-untranslated region polymorphisms associated with risk and progression of squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9413-7

21 January 2018

Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9413-7

21 January 2018

Case-control analysis of thymidylate synthase polymorphisms and risk of lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9413-7

21 January 2018

Genetic polymorphisms of ataxia telangiectasia mutated affect lung cancer risk.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

25 October 2018

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

25 October 2018

Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

25 October 2018

Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

25 October 2018

Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

25 October 2018

Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

25 October 2018

Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3110647

25 October 2018

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20306339

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel thymidylate synthase enhancer region alleles in African populations

1 reference

https://pubmed.ncbi.nlm.nih.gov/20306339

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/20306339

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/20306339

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Functional Analysis and DNA Polymorphism of the Tandemly Repeated Sequences in the 5'-terminal Regulatory Region of the Human Gene for Thymidylate Synthase

1 reference

https://pubmed.ncbi.nlm.nih.gov/20306339

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-010-9413-7

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

release_2smt37jcird2fcrmkn2swf3rs4

1 reference

https://api.fatcat.wiki/v0/release/2smt37jcird2fcrmkn2swf3rs4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35032865&oldid=2197173023"